The metabolism of two carcinogenic polynuclear aromatic hydrocarbons, benzo[a]pyrene (BP) and 7,12-dimethylbenz[a]anthracene, was studied in explants of human pancreatic duct and bronchus cultured in a chemically defined medium. In cultured human bronchial mucosa, activity of aryl hydrocarbon hydroxylase was inducible by both benz[a]anthracene and BP. Prior exposure of the bronchial explants to benz[a]anthracene altered the qualitative features of the metabolite profile of BP as analyzed by high-pressure liquid chromatography. The metabolite profiles of BP produced by normal-appearing bronchi from patients with lung cancer were also compared with those from patients without lung cancer. The profiles were similar except for an observed higher percentage of organic solvent-extractable metabolites formed by bronchi from the noncancer patients that eluted from the column as a single peak. This peak cochromatographed with both the 9,10-diol and a triol of BP. 7,12-Dimethylbenz[a]anthracene was bound to the DNA of cultured human bronchial cells at higher levels than was BP. Binding of 7,12-dimethylbenz[a]anthracene to DNA in human pancreatic duct was consistently less than that in cultured bronchi in the 5 patients studied. Human pancreatic duct and bronchus have the capacity to activate polynuclear aromatic hydrocarbons into metabolic intermediates that bind to DNA and, presumably, into ultimate carcinogens.

This content is only available via PDF.